Vitamin K Status and Lower Extremity Function in Older Adults: The Health Aging and Body Composition Study by Shea, M. Kyla et al.
© The Author 2015. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved.  
For permissions, please e-mail: journals.permissions@oup.com.
1348
Journals of Gerontology: Medical Sciences
cite as: J Gerontol A Biol Sci Med Sci, 2016, Vol. 71, No. 10, 1348–1355
doi:10.1093/gerona/glv209
Advance Access publication November 17, 2015
Research Article
Vitamin K Status and Lower Extremity Function in Older 
Adults: The Health Aging and Body Composition Study 
M. Kyla  Shea,1 Richard F.  Loeser,2 Fang-Chi  Hsu,3 Sarah L.  Booth,1 Michael  Nevitt,4 
Eleanor M. Simonsick,5 Elsa S. Strotmeyer,6 Cees Vermeer,7 and Stephen B. Kritchevsky8 
for the Health ABC Study 
1Tufts University USDA Human Nutrition Research Center on Aging, Boston, Massachusetts. 2Division of Rheumatology, Allergy and 
Immunology, University of North Carolina, Chapel Hill. 3Division of Public Health Sciences, Wake Forest School of Medicine, Winston-
Salem North Carolina. 4Department of Epidemiology and Biostatistics, University of California San Francisco. 5National Institute on Aging/
NIH Baltimore, Maryland. 6Graduate School of Public Health, University of Pittsburgh, Pennsylvania. 7VitaK, University of Maastricht, 
Netherlands. 8Sticht Center on Aging, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Address correspondence to Kyla Shea, PhD, USDA Human Nutrition Research Center on Aging at Tufts University, 711 Washington St., Boston 
MA. E-mail: kyla.shea@tufts.edu
Received March 24, 2015; Accepted October 22, 2015
Decision Editor: James Goodwin, PhD
Abstract
Background: While low vitamin K status has been associated with several chronic diseases that can lead to lower extremity disability, it is not 
known if low vitamin K status is associated with worse lower extremity function.
Methods: Vitamin K status was measured according to plasma phylloquinone (vitamin K1) and dephosphorylated-uncarboxylated MGP 
(dp-ucMGP) in 1,089 community-dwelling older adults (mean ± SD age =74 ± 3 years; 67% female). Lower extremity function was assessed 
using the short physical performance battery (SPPB), gait speed, and isokinetic leg strength. Linear regression and mixed models were used to 
determine the cross-sectional and longitudinal associations between vitamin K status and functional outcome measures.
Results: Cross-sectionally, higher plasma phylloquinone was associated with better SPPB scores and 20-m gait speed (p ≤ .05). After 4–5 years, 
those with ≥1.0 nM plasma phylloquinone (the concentration achieved when recommended intakes are met) had better SPPB scores (p = .03) and 
20-m gait speed (p < .05). Lower plasma dp-ucMGP (reflective of better vitamin K status) was associated with better SPPB scores and leg strength 
cross-sectionally (p ≤ .04), but not longitudinally. Neither measure of vitamin K status was associated with walking endurance or with the rate 
of decline in function.
Conclusion: Older adults with higher vitamin K status had better physical performance scores at baseline, but data are less consistent 
longitudinally. Since lower extremity disability is a common consequence of multiple chronic diseases for which a role of vitamin K has been 
suggested, future studies are needed to determine if vitamin K supplementation could improve function in those with vitamin K insufficiency 
and clarify underlying mechanism(s).
Keywords: Physical performance—Nutrition—Physical function—Vitamin K
Vitamin K is an essential fat-soluble nutrient found mainly in green 
leafy vegetables and vegetable oils that functions primarily as an enzy-
matic cofactor in the carboxylation of vitamin K-dependent proteins. 
While the most-known vitamin K-dependent proteins are coagula-
tion proteins, several others are present in vascular, skeletal, and other 
extra-hepatic tissues, suggesting multiple roles for vitamin K in health 
and disease (1). For example, matrix gla protein (MGP) is a vitamin 
K-dependent protein in vascular tissue, cartilage, and bone that inhibits 
mineralization when it is carboxylated—which requires vitamin K (2). 
Uncarboxylated MGP does not inhibit soft-tissue mineralization (3). 
Independent of this enzymatic cofactor role, vitamin K was shown to 
suppress inflammatory cytokine production in rodent models suggest-
ing it has anti-inflammatory effects (4). At the population level, low 
vitamin K status has been associated with more cardiovascular disease, 
osteoarthritis, metabolic syndrome, and inflammation (5–8). These 
conditions are associated with lower extremity disability (9–11).
Impaired lower extremity function is a risk factor for disability 
and mortality (12,13) While the etiology of functional impairment 
is complex, the presence of age-related comorbidities increases the 
likelihood of developing or having worse impairment (14). More 
than 75% of adults over age 65 have more than one chronic disease 
(15) and older adults with multiple chronic disease are more likely 
to have impaired physical function than those with one condition 
(14,16). Mechanisms common to chronic diseases associated with 
impaired function represent possible targets to reduce functional 
decline. While weight loss and physical activity are two approaches 
that reduce functional decline in older age (17,18), vitamin K 
may represent an alternate novel and readily modifiable approach 
because vitamin K-dependent mechanisms are implicated in mul-
tiple comorbidities associated with functional decline (1). To our 
knowledge the association between vitamin K status and lower 
extremity function has not yet been reported. The purpose of this 
study was test the hypothesis that older community-dwelling adults 
with better vitamin K status would have better lower extremity 
function and less functional decline.
Methods
A detailed description of participants, outcome, exposure, and 
covariate measurements, and statistical analyses is included in the 
Supplementary Methods.
Participants were drawn from the Health, Aging and Body 
Composition Study (Health ABC, n  =  3,075), a prospective lon-
gitudinal cohort study designed to examine age-related changes in 
physical function and body composition in older black and white 
adults. Health ABC recruitment has been well-described (19). 
When enrolled, all participants were free of disability in activities 
of daily living and reported no difficulty walking 1/4 mile or up 
10 steps. Vitamin K status was measured in 1,133 participants in 
the knee osteoarthritis substudy, initiated at the year 2 clinic visit 
(1998–99) to examine the relationship between knee osteoarthritis 
and functional decline. The Health ABC knee osteoarthritis sub-
study included 836 participants with knee pain and 297 randomly 
selected controls without knee pain. Knee pain was defined as 
“knee pain, aching, or stiffness on most days for at least 1 month” 
at some point over the previous year or moderate or worse knee 
pain during the previous month in association with at least one 
activity on the WOMAC knee pain scale (8). All participants pro-
vided written informed consent and the institutional review boards 
at both study sites approved all protocols.
Lower Extremity Function
In years 1, 4, and 6 physical performance was assessed using the 
short physical performance battery (SPPB) (20). To minimize ceiling 
effects, the Health ABC PPB was also administered (19). Usual gait 
speed over 20 m and endurance over 400 m was assessed in years 
2, 4, and 6 using a 20-m course marked with cones at each end, 
as described (19). Knee extensor strength was measured at years 2, 
4, and 6 using an isokinetic dynamometer (Kin-com, model 125AP, 
Chattecx Corp., Chattanooga, TN) as described (19). Exclusion cri-
teria for lower extremity function tests are described in detail else-
where (19).
Vitamin K Status
Vitamin K status was measured according to plasma phylloquinone 
and desphospho-uncarboxylated MGP (dp-ucMGP) from the same 
citrated samples collected at the year 2 clinic visit (1998/99) after 
an overnight fast. All samples were stored at −70°C until analysis. 
Plasma phylloquinone was measured using reversed-phase HPLC 
(Tufts University (21)). Plasma dp-ucMGP was measured using a 
sandwich ELISA (VitaK, University of Maastricht (22)). This form 
of circulating MGP is reduced in response to phylloquinone sup-
plementation (23).
Covariates
The following covariates were assessed, as described in the 
Supplementary Methods: age, sex, race, site, education, triglycerides, 
total cholesterol, smoking, alcohol use, healthy eating index, energy 
intake, fat intake, 25(OH)D, creatinine, time spent walking per week, 
depression, diabetes, lipid lowering medication use, antihypertension 
medication use, BMI, systolic blood pressure, interleukin-6 (IL-6), 
cognitive status, and anti-inflammatory medication use.
Statistical Analyses
Linear regression and mixed models were used to determine the 
cross-sectional and longitudinal associations between vitamin K sta-
tus and lower extremity function. Based on previous work, plasma 
phylloquinone was categorized as <0.2, 0.2–<1.0, or ≥1.0 nM (8). 
Concentrations <0.2 nM are generally achieved when dietary intakes 
are ≤20% of current recommendations and 1.0 nmol/L is the con-
centration that is generally achieved when adequate intakes are met, 
based on metabolic feeding studies (24). Given the lack of estab-
lished dp-ucMGP normal ranges, categories were based on distribu-
tion tertiles. All analyses were carried out in SAS v.9.3 (Cary, NC). 
Significance was set at two-sided alpha of 0.05.
Results
Our study population was 60% female, 47% black, with a mean ± 
SD BMI of 28.0 ± 5.0 kg/m2. Over 61% had plasma phylloquinone 
<1.0 nM and nearly 8% had concentrations <0.2 nM. Participant 
characteristics according to plasma phylloquinone category are 
shown in Table 1. Participants with ≥1.0 nM plasma phylloquinone 
had higher triglycerides and total cholesterol, were more likely to 
be female, from Memphis, and less likely to smoke. Participant 
characteristics according to plasma dp-ucMGP tertile are shown in 
Supplementary Table 1. Those with low dp-ucMGP had lower tri-
glycerides and circulating IL-6, were more likely to be black and less 
likely to take anti-inflammatory medication.
Cross-sectionally, higher plasma phylloquinone was associ-
ated with higher SPPB scores (p < .01) and faster 20-m gait speed 
(p = .05) after adjustment (Table 2). Lower dp-ucMGP was associ-
ated with higher SPPB scores cross-sectionally (p ≤ .05) and with 
higher isokinetic leg strength (p =  .04). Neither vitamin K status 
measure was significantly associated with 400-m gait speed (both p 
≥ .45) nor with ability to complete the 400-m walk (both p ≥ .45).
Longitudinally, participants with plasma phylloquinone ≥1.0 nM 
had higher physical performance scores and faster usual gait speed 
at 4–5 years of follow-up, fully-adjusted (Table 3; Figure 1). Plasma 
phylloquinone was not associated with isokinetic leg strength, 
400-m gait speed, or ability to complete 400-m walk longitudinally. 
Participants in the lower dp-ucMGP tertiles had better Health ABC 
physical performance scores over time compared to the highest 
tertile, but plasma dp-ucMGP was not associated with any other 
performance outcome during follow-up (fully-adjusted) (Table 3; 
Figure 2). Although all performance outcomes declined over time, 
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the rate of decline was similar across the plasma phylloquinone 
groups (phylloquinone category*time interaction all p > .25) and 
dp-ucMGP tertiles (dp-ucMGP tertile*time interaction all p > .10). 
The interaction between sex/race and vitamin K status were not sta-
tistically significant (p values for sex interactions >0.32 and for race 
interactions >0.06).
When unadjusted models were restricted to those with com-
plete covariate data, the results were similar. We also stratified by 
whether participants had qualifying knee pain or not (on account 
of this Health ABC subgroup’s selection (8)). The results in both 
groups were generally consistent with the direction of our overall 
findings, but statistical significance was attenuated because sample 
sizes were reduced (n = 799 with knee pain, 290 without) (data not 
shown.)
Discussion
We hypothesized higher vitamin K status would be associated with 
better lower extremity function because higher vitamin K status has 
been associated with a lower prevalence and progression of several 
comorbidities that have been associated with impaired function 
and disability (5–8). We found generally healthy older adults with 
≥1.0 nM plasma phylloquinone had better physical performance 
scores and better usual gait speed cross-sectionally and at 4–5 fol-
low-up years compared to those with <1.0 nM plasma phylloqui-
none. The rate of decline did not differ by plasma phylloquinone 
status. Lower plasma dp-ucMGP (reflective of better vitamin K sta-
tus) was associated with better lower extremity performance and 
isokinetic leg strength cross-sectionally and with better Health ABC 
physical performance scores (but not SPPB scores) over time. Neither 
Table 1. Baseline Characteristics of Health ABC Participants According to Plasma Phylloquinone Category
<0.2 nM
n = 84
0.2–<1.0 nM
n = 585
≥1.0 nM
n = 419 p*
Age, y 74.8 ± 2.6 74.8 ± 3.0 74.4 ± 2.8 .13
Female (n [%]) 47 (56) 334 (57) 270 (64) .05
Black (n [%]) 43 (51) 265 (45) 200 (48) .53
Pittsburgh (n [%]) 56 (67) 331 (57) 190 (45) <.01
BMI, kg/m2 27.9 ± 5.2 27.9 ± 5.0 28.4 ± 5.0 .07
Triglycerides, mg/dL† 111 ± 44 129 ± 39 161 ± 100 <.01
Total cholesterol, mg/dl 200 ± 36 205 ± 39 210 ± 42 .04
IL-6, pg/ml† 4.1 ± 4.1 3.6 ± 3.9 2.5 ± 3.8 .11
Creatinine, mg/dl† 1.0 ± 0.3 1.0 ± 0.2 1.0 ± 0.2 .70
25(OH)D, ng/ml 25.4 ± 9.4 25.2 ± 11.1 25.2 ± 10.0 .99
dp-ucMGP, pM† 477 ± 323 508 ± 409 401 ± 339 <.01
Healthy Eating Index score 68 ± 12 69 ± 12 70 ± 12 .23
Energy intake, kcal/day 1872 ± 827 1882 ± 778 1794 ± 653 .30
Fat intake, g/day 71 ± 41 71 ± 37 69 ± 33 .45
Systolic blood pressure, mmHg 132 ± 18 135 ± 21 135 ± 20 .62
Diabetes (n [%]) 11 (13) 100 (17) 77 (18) .49
Lipid lowering medication (n [%]) 13 (15) 90 (15) 69 (16) .90
Anti-hypertension medication (n [%]) 40 (47) 325 (56) 265 (63) <.01
Anti-inflammatory medication ( n[%]) 41 (49) 336 (58) 247 (59) .23
Cognitive function (3MS score)† 88 ± 8 90 ± 8 90 ± 8 .22
Depression (CESD10 score)† 3.8 ± 4.0 3.2 ± 3.2 3.2 ± 3.5 .96
Walking, min/week
 0 35 (42) 266 (46) 172 (41) .11
 1–149 34 (40) 166 (28) 139 (33)
 ≥150 15 (18) 152 (26) 109 (26)
Smokers (n [%])
 Current 12 (14) 59 (10) 28 (7) .04
 Former 40 (48) 254 (43) 172 (41)
Alcohol intake (n [%])
 None 39 (46) 321 (55) 218 (52) .62
 ≤7 per week 39 (46) 227 (39) 173 (41)
 >1 per day 6 (7) 34 (6) 27 (7)
Education
 <High school 29 (35) 153 (26) 114 (39) .51
 High school graduate 22 (27) 196 (34) 141 (34)
 College graduate 32 (39) 235 (40) 164 (39)
Season (n [%])
 Dec–Feb 13 (16) 155 (27) 100 (24) <.01
 Mar–May 5 (6) 171 (29) 134 (32)
 June–Aug 24 (29) 93 (16) 90 (21)
 Sep–Nov 42 (50) 166 (28) 96 (23)
Note: Mean ± SD unless indicated otherwise.
*Based on one-way ANOVA or Kruskal–Wallis (continuous outcomes) or Chi-square test (categorical outcomes).
†Outcome natural log-transformed for ANOVA, means ± SDs are presented in original scale.
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measure of vitamin K status was associated with lower extremity 
endurance as measured according to 400-m walk gait speed. This 
may reflect task specificity such that vitamin K status could be more 
relevant to low-endurance functional tasks (eg, standing from a 
chair) than to tasks requiring more endurance (eg, walking around 
the neighborhood).
Our finding that plasma phylloquinone was associated with 
lower extremity function is novel and suggests plasma phylloquinone 
≥1.0 nM is beneficial with respect to maintaining lower extremity 
physical performance and usual gait speed over 4–5 years. A concen-
tration of ≥1.0 nM is generally achieved when recommended vitamin 
K intakes (90–120 mcg/day) are met (24). There is not an established 
threshold of circulating phylloquinone that defines sufficient/insuf-
ficient and low circulating phylloquinone has not been consistently 
defined in population-based studies (5,7,8). Identifying the threshold 
of circulating vitamin K that is sufficient to meet all physiological 
needs is an area of research that needs attention. Since low circu-
lating phylloquinone is easily corrected, substantiating our findings 
in future studies could have an important public-health impact on 
physical function in older age.
Dp-ucMGP was associated with SPPB cross-sectionally but not 
longitudinally. However, lower dp-ucMGP was associated with better 
Health ABC performance scores over time. The Health ABC perfor-
mance battery was designed to reduce potential ceiling effects of the 
SPPB since Health ABC participants were well-functioning at base-
line (25). This may explain why dp-ucMGP was differentially asso-
ciated with the two performance batteries. Because the Health ABC 
performance battery was the only performance measure that was 
associated with dp-ucMGP longitudinally, chance cannot be ruled out 
as a possible explanation. In an earlier analysis of this same cohort 
plasma dp-ucMGP was associated with structural characteristics of 
knee osteoarthritis cross-sectionally but not over follow-up (8), which 
may suggest (dp)ucMGP is not causally related to these health out-
comes. It is also possible vitamin Ks role in functional decline could be 
through mechanisms that do not involve MGP. Vitamin K-dependent 
proteins other than MGP are implicated in physiological processes 
that lead to functional impairment (26,27). Phylloquinone has been 
shown to reduce expression of proinflammatory cytokines (4). Low 
grade inflammation is a characteristic of aging and has been linked to 
functional impairment (11). This could be an additional mechanism 
Table 2. Cross-Sectional Associations Between Vitamin K Status and Lower Extremity Function in Health ABC
Plasma Phylloquinone n <0.2 nM 0.2–<1.0 nM ≥1.0 nM p Trend*
SPPB (0–12)
 Unadjusted 1,089 9.61 ± 0.17 9.86 ± 0.06 10.07 ± 0.07 <.01
 Adjusted† 982 9.58 ± 0.19 9.74 ± 0.12 9.98 ± 0.13 <.01
Health ABC PPB (0–4)
 Unadjusted 1,059 2.09 ± 0.06 2.13 ± 0.02 2.19 ± 0.03 .05
 Adjusted† 954 2.06 ± 0.08 2.10 ± 0.04 2.18 ± 0.04 <.01
Usual 20M walk (m/s)
 Unadjusted 1,079 1.11 ± 0.03 1.10 ± 0.02 1.12 ± 0.02 .21
 Adjusted† 980 1.09 ± 0.03 1.09 ± 0.01 1.12 ± 0.02 .05
Isokinetic leg strength (nm/kg lean)
 Unadjusted 924 13.51 ± 0.43 13.17 ± 0.16 13.46 ± 0.19 .53
 Adjusted 847 12.94 ± 0.49 12.89 ± 0.30 13.40 ± 0.32 .06
400M walk, m/s‡
 Unadjusted 721 1.27 ± 0.04 1.25 ± 0.02 1.25 ± 0.01 .82
 Adjusted† 667 1.21 ± 0.03 1.23 ± 0.03 1.23 ± 0.04 .68
Plasma dp-ucMGP n T1: ≤ 267 pM T2: 268–566 pM T3: ≥567 pM p trend†
SPPB (0–12)
 Unadjusted 1,089 10.07 ± 0.08 9.96 ± 0.08 9.73 ± 0.08 <.01
 Adjusted† 982 9.98 ± 0.13 9.80 ± 0.13 9.57 ± 0.14 <.01
Health ABC PPB (0–4)
 Unadjusted 1,059 2.18 ± 0.03 2.16 ± 0.03 2.11 ± 0.03 .09
 Adjusted† 954 2.16 ± 0.04 2.13 ± 0.04 2.08 ± 0.05 .05
Usual 20M walk, m/s
 Unadjusted 1,079 1.10 ± 0.01 1.12 ± 0.01 1.11 ± 0.01 .57
 Adjusted† 980 1.10 ± 0.02 1.10 ± 0.02 1.10 ± 0.02 .76
Isokinetic leg strength, nm/kg lean
 Unadjusted 924 13.36 ± 0.20 13.39 ± 0.20 13.18 ± 0.21 .54
 Adjusted 847 13.32 ± 0.33 13.10 ± 0.31 12.74 ± 0.34 .04
400M walk, m/s‡
 Unadjusted 721 1.23 ± 0.01 1.26 ± 0.01 1.27 ± 0.02 .10
 Adjusted† 667 1.22 ± 0.04 1.23 ± 0.03 1.24 ± 0.04 .45
Note: Data are means (or LS means) ± SEM.
*Trend test based on general linear model using category as an ordinal exposure (1–3).
†Adjusted for age, sex, race, site, education, triglycerides, total cholesterol, smoking, alcohol use, healthy eating index, energy intake, fat intake, 25(OH)D, 
creatinine, depression, diabetes, lipid-lowering medication use, anti-hypertension medication use, BMI, systolic blood pressure, IL-6, cognitive status, anti-inflam-
matory medication use, walking time per week.
‡In those who completed the test (66%).
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Table 3. Associations Between Vitamin K Status and Lower Extremity Function Over Time in Health ABC Knee OA Study Participants
n
Plasma Phylloquinone p Value
<0.2 nM 0.2–<1.0 nM ≥1.0 nM Within year
Plasma phylloquinone × 
year interaction
Overall plasma 
phylloquinone
SPPB (0–12)
 Unadjusted
  Year 1 1,088 9.60 (0.17) 9.83 (0.06) 10.05 (0.07) .013 0.195 0.031
  4 964 9.26 (0.25) 9.23 (0.10) 9.42 (0.11) .448
  6 853 8.49 (0.30) 8.44 (0.12) 8.93 (0.13) .021
 Adjusted
  Year 1* 987 9.67 (0.18) 9.83 (0.10) 10.07 (0.10) .017 0.250 0.035
  4 843 9.46 (0.24) 9.39 (0.12) 9.54 (0.13) .580
  6 706 8.61 (0.29) 8.72 (0.13) 9.14 (0.15) .031
Health ABC PPB (0–4)
 Unadjusted
  Year 1 1,058 2.09 (0.06) 2.11 (0.02) 2.18 (0.03) .103 0.380 0.078
  4 947 1.93 (0.07) 1.91 (0.03) 1.96 (0.03) .436
  6 819 1.68 (0.08) 1.69 (0.03) 1.80 (0.03) .035
 Adjusted
  Year 1* 959 2.07 (0.06) 2.06 (0.03) 2.13 (0.04) .024 0.259 0.033
  4 840 1.90 (0.07) 1.89 (0.04) 1.93 (0.04) .444
  6 704 1.63 (0.08) 1.68 (0.03) 1.78 (0.03) .022
Usual 20M gait speed, m/s
 Unadjusted
  Year 2 1,078 1.11 (0.02) 1.10 (0.01) 1.12 (0.01) .363 0.547 0.069
  4 932 1.09 (0.03) 1.08 (0.01) 1.12 (0.01) .085
  6 811 1.01 (0.02) 1.03 (0.01) 1.06 (0.01) .049
 Adjusted
  Year 2* 987 1.10 (0.02) 1.10 (0.01) 1.12 (0.01) .105 0.925 0.002
  4 832 1.10 (0.02) 1.11 (0.01) 1.14 (0.01) .181
  6 696 1.04 (0.03) 1.06 (0.01) 1.09 (0.01) .047
Isokinetic leg strength, nm/kg lean
 Unadjusted
  Year 2 923 13.28 (0.42) 13.11 (0.16) 13.30 (0.18) .718 0.192 0.602
  4 806 12.32 (0.37) 12.44 (0.15) 12.47 (0.17) .937
  6 742 11.11 (0.40) 11.68 (0.16) 11.93 (0.18) .153
 Adjusted
  Year 2* 851 12.97 (0.44) 12.87 (0.25) 13.17 (0.27) .433 0.357 0.296
  4 726 11.99 (0.41) 12.22 (0.25) 12.35 (0.26) .643
  6 643 10.91 (0.44) 11.52 (0.26) 11.82 (0.27) .105
400M gait speed, m/s†
Unadjusted
  Year 2 720 1.26 (0.04) 1.25 (0.02) 1.24 (0.02) .897 0.985 0.976
  4 603 1.21 (0.03) 1.22 (0.01) 1.22 (0.01) .966
  6 515 1.13 (0.03) 1.14 (0.01) 1.14 (0.01) .991
Adjusted
  Year 2* 670 1.22 (0.04) 1.23 (0.02) 1.22 (0.01) .949 0.934 0.605
  4 548 1.17 (0.03) 1.20 (0.02) 1.20 (0.02) .562
  6 460 1.09 (0.03) 1.13 (0.02) 1.13 (0.02) .445
n
Plasma dp-ucMGP p value
T1:
≤267 pM
T2:
268–566 pM
T3:
≥ 567 pM Within year
Plasma dp-ucMGP*year 
interaction
Overall  
dp-ucMGP
SPPB (0–12)
 Unadjusted
  Year 1 1,088 10.04 (0.08) 9.94 (0.08) 9.71 (0.08) .012 0.592 0.019
  4 964 9.37 (0.12) 9.47 (0.12) 9.07 (0.12) .056
  6 853 8.81 (0.14) 8.71 (0.14) 8.38 (0.15) .094
 Adjusted
  Year 1* 987 10.07 (0.11) 9.92 (0.11) 9.70 (0.11) .008 0.578 0.035
  4 843 9.48 (0.13) 9.59 (0.13) 9.27 (0.14) .131
  6 706 8.97 (0.15) 8.97 (0.16) 8.65 (0.17) .181
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through which vitamin K influences physical function. Additional 
research is needed to clarify the role of MGP and other vitamin 
K-dependent mechanisms in physical performance.
Our study is strengthened by including cross-sectional and lon-
gitudinal components in a well-characterized cohort with multiple 
measures of lower extremity function. However, the observational 
design precludes causal inferences. At the time of enrollment, Health 
ABC participants reported being well-functioning, which could limit 
the generalizability to less functional groups. Participants included in 
this analysis were selected because they had qualifying knee pain or 
were a randomly selected control without knee pain (8). When partici-
pants with and without knee pain were analyzed separately, the strati-
fied results were generally consistent to our overall findings (although 
not statistically significant). Plasma phylloquinone and dp-ucMGP did 
not differ according to knee pain status (both p > .38), but persons 
with knee pain had worse function. Given our sample size and that the 
majority of participants in our study had knee pain, larger studies are 
needed to clarify if vitamin K is more relevant to function in persons 
with knee pain or in older adults overall. The clinical relevance of our 
findings is also uncertain. In older adults more functionally impaired 
than Health ABC participants, a 0.3–0.5 unit difference in SPPB was 
found to be a minimally meaningful change, and for usual gait speed a 
0.04–0.05 m/s difference was considered clinically meaningful (28,29). 
Our results suggest participants with ≥1.0 nM plasma phylloquinone 
had a 0.3 unit higher SPPB score at baseline and a 0.4 unit higher 
SPPB score after 5 years compared to participants with <1.0 nM. The 
difference in usual gait speed between these two groups after 4 years 
was 0.04 m/s. At the 2–3-year follow-up, we did not detect differences 
in any outcome across categories of plasma phylloquinone, although 
significant differences in SPPB were detected at baseline and after 
5 years and differences in usual gait speed were detected after 4-year 
follow-up as well. The explanation for this observation is unclear. Had 
our follow-up been limited to 2 years, we would have concluded that 
plasma phylloquinone was not associated with functional impairment 
n
Plasma dp-ucMGP p value
T1:
≤267 pM
T2:
268–566 pM
T3:
≥ 567 pM Within year
Plasma dp-ucMGP*year 
interaction
Overall  
dp-ucMGP
Health ABC PPB (0–4)
 Unadjusted
  Year 1 1,058 2.16 (0.03) 2.16 (0.03) 2.10 (0.03) .240 0.281 0.031
  4 947 1.95 (0.03) 1.98 (0.03) 1.86 (0.03) .033
  6 819 1.78 (0.04) 1.77 (0.04) 1.65 (0.04) .031
 Adjusted
  Year 1* 959 2.10 (0.04) 2.09 (0.04) 2.04 (0.04) .238 0.338 0.024
  4 840 1.93 (0.04) 1.94 (0.04) 1.84 (0.04) .049
  6 704 1.76 (0.05) 1.73 (0.05) 1.63 (0.05) .021
Usual 20M walk, m/s
 Unadjusted
  Year 2 1,078 1.10 (0.01) 1.12 (0.01) 1.11 (0.01) .523 0.458 0.318
  4 932 1.09 (0.01) 1.11 (0.01) 1.10 (0.01) .426
  6 811 1.03 (0.01) 1.06 (0.01) 1.02 (0.01) .169
 Adjusted
  Year 2* 987 1.11 (0.01) 1.11 (0.01) 1.11 (0.02) .895 0.705 0.712
  4 832 1.11 (0.01) 1.12 (0.01) 1.13 (0.01) .529
  6 696 1.07 (0.01) 1.07 (0.01) 1.07 (0.01) .976
Isokinetic leg strength, nm/kg lean
 Unadjusted
  Year 2 923 13.18 (0.20) 13.30 (0.20) 13.10 (0.20) .783 0.722 0.627
  4 806 12.59 (0.18) 12.48 (0.18) 12.24 (0.19) .396
  6 742 11.86 (0.20) 11.71 (0.20) 11.63 (0.20) .711
 Adjusted
  Year 2* 851 13.11 (0.27) 13.01 (0.27) 12.79 (0.29) .485 0.905 0.227
  4 726 12.49 (0.27) 12.21 (0.27) 11.97 (0.28) .162
  6 643 11.79 (0.28) 11.50 (0.29) 11.39 (0.30) .366
400M walk, m/s†
 Unadjusted
  Year 2 720 1.23 (0.02) 1.25 (0.02) 1.27 (0.02) .324 0.102 0.301
  4 603 1.24 (0.02) 1.24 (0.01) 1.20 (0.01) .187
  6 515 1.11 (0.01) 1.15 (0.01) 1.14 (0.01) .202
Adjusted
  Year 2* 670 1.22 (0.03) 1.22 (0.02) 1.24 (0.03) .691 0.165 0.856
  4 548 1.21 (0.02) 1.21 (0.02) 1.18 (0.02) .252
  6 460 1.12 (0.02) 1.13 (0.02) 1.13 (0.02) .658
*Adjusted for age, sex, race, site, education, triglycerides, total cholesterol, smoking, alcohol use, healthy eating index, energy intake, fat intake, 25(OH)D, 
creatinine, physical activity, depression, diabetes, lipid lowering medication use, anti-hypertension medication use, and time-varying BMI, systolic blood pressure, 
IL-6, cognitive status, anti-inflammatory medication use, time spent walking per week.
†In those who completed the test (66%). 
Table 3. Continued
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longitudinally. With repeated measures we could account for changes 
in status over time, but vitamin K status measures were only available 
at a single time point. The primary dietary sources of phylloquinone 
are characteristic of healthy diets (30) and higher circulating phyllo-
quinone can reflect healthy lifestyles, which could be associated with 
better function itself. Although we adjusted our models for multiple 
co-morbidities, medication use, and multiple characteristics that could 
reflect general good health (diet and physical activity), residual con-
founding may persist. 
In conclusion, older community-dwelling adults with ≥1.0 nM 
plasma phylloquinone had better physical performance battery 
scores cross-sectionally and over 4–5 follow-up years. Those with 
Figure 1. Plasma phylloquinone and (A) SPPB score, (B) Health ABC PPB score, (C) 20-meter gait speed, (D) isokinetic leg strength. Data are fully-adjusted LS 
means, error bars are SEM. 
Figure 2. Plasma dp-ucMGP and (A) SPPB score, (B) Health ABC PPB score, (C) 20-meter gait speed, (D) isokinetic leg strength. Data are fully-adjusted LS means, 
error bars are SEM. 
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higher plasma phylloquinone also had better usual gait speed at 
4 years of follow-up, but plasma phylloquinone status was not asso-
ciated with walking endurance. The findings with an independent 
functional marker of vitamin K status were less consistent. Low vita-
min K status has been associated with multiple co-morbidities that 
lead to impaired function and disability (5–8), so improving vitamin 
K status may reduce functional decline in older adults with various 
age-related conditions. Future studies are needed to confirm our find-
ings, establish if vitamin K supplementation reduces lower extrem-
ity functional decline in older age and to clarify the mechanism(s) 
underlying vitamin Ks role in this process.
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